AEON Biopharma Amends Warrant Terms to Secure $6.2 Million in Proceeds
AEON Biopharma has entered into an agreement to reduce the exercise price of its two-year milestone warrants, expecting to generate approximately $6.2 million in gross proceeds.
Stocks · News reference
8-K filing — AEON Biopharma, Inc. (AEON)
Filed: 2026-11-03 AccNo: 0001837607-26-000081 Size: 207 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for HPE, Phillips 66, Micron and AEON; cut targets for Liquidia, Apple and Zions.
Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2
AEON Biopharma shares are trading higher after the company announced that the FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX may be submitted as supportive evidence.
AEON Biopharma Says FDA Indicated Prior Head-To-Head Studies Vs. Botox Can Be Submitted As Supportive Evidence For ABP-450 Biosimilar
AEON Biopharma shares are trading higher after the company reported pilot study results showing its ABP‑450 had comparable potency loss and oxidation patterns to Botox under thermal and oxidative stress.